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Abstract Background: Use of magnetic resonance cholangiopancreatography
(MRCP) for confirmation of presence of biliary obstruction is virtually risk-free.
However, unlike diagnostic endoscopic retrograde cholangiopancreatography
(ERCP), no therapeutic option can be offered simultaneously with MRCP. The aim
of the study is to assess the cost-effectiveness of MRCP when compared with the
conventional practice of diagnostic ERCP for the investigation of biliary obstruction
in adults.
Methods: Cost-effectiveness analysis from the perspective of the health care pro-
vider. Sensitivity analysis includes presentation of a family of cost effectiveness ac-
ceptability curves and the impact of different risks of common bile duct stones
associated with ultrasound and liver function test results. The main outcome mea-
sure is cost per quality adjusted life year (QALY).
Results: Baseline results, at 37% probability of common bile duct stones, show that
MRCP is the dominant strategy, with expected savings of £149 (£325 to £15) and
expected QALY gain of 0.011 (0e0.030) per case. The probability of avoiding unnec-
essary therapeutic ERCP is 30%. For patients at high risk of common bile duct stones
(probability >60%) ERCP is the preferable strategy.
* Corresponding author. Tel.: þ44 (0)1904 321461.
E-mail address: yb3@york.ac.uk (Y. Bravo).1743-9191/$ - see front matter ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijsu.2006.01.007
Economic evaluation of MRCP compared to diagnostic ERCP 13Conclusions: The baseline estimate is that MRCP would be both cost saving and
would result in improved quality of life outcomes compared to diagnostic ERCP,
but its potential sources of economic benefit are highly dependent on access to,
and waiting lists for adequate MRI technology at hospital level.
ª 2006 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
Use of magnetic resonance cholangiopancreatog-
raphy (MRCP) for confirmation of presence of
biliary obstruction is virtually risk-free and its
fixed cost is only about half that of diagnostic
endoscopic retrograde cholangiopancreatography
(ERCP). However, no therapeutic option can be
offered simultaneously with MRCP, unlike ERCP;
there is thus a trade off between increased di-
agnostic costs in patients who ultimately require
invasive treatment and cost and health benefits for
patients who can avoid an unnecessary invasive
diagnostic procedure. In the absence of direct
economic evidence on this trade off a model based
assessment is required. Our model incorporates
the most frequent conditions affecting the biliary
tree, such as common bile duct stones (CBDS),
benign biliary strictures and peripancreatic can-
cer.1 The UK NHS R&D Programme commissioned
this assessment of the clinical and cost effective-
ness of MRCP compared to the conventional
practice of diagnostic ERCP for an adult UK popula-
tion. A monograph in the Health Technology
Assessment series gives further details of
methods.2
Almost all patients with symptoms suspected to
be of biliary origin in the UK will be referred for
ultrasound (US) either by the general practitioner
or specialist.3 Patients for whom MRCP is contrain-
dicated (i.e. exclusions for MRI, such as claustro-
phobia and cardiac pacemakers) or ERCP (i.e.
previous gastric surgery) are excluded from the
scope of the model. Cholangiocarcinoma in the in-
trahepatic bile duct and primary sclerosing cholan-
gitis (PSC) were both excluded because they are
uncommon conditions normally associated with
liver treatment.
The economic and clinical impact of MRCP or
ERCP is highly dependent on the incidence of CBDS
in the patient groups being considered. Previous
research has estimated the incidence of CBDS
within populations demonstrating different US
and liver function test (LFT) results.4 The eco-
nomic impact of MRCP compared to ERCP within
these patient groups together with higher risk
groups is explored.Methods
A probabilistic economic model was constructed in
order to evaluate the relative cost-effectiveness of
adopting MRCP scanning compared to diagnostic
ERCP for the investigation of biliary obstruction in
adults. The primary outcome measure for the
economic evaluation was cost per quality adjusted
life year (QALY). The decision problem is illus-
trated in the structure of the decision tree pre-
sented in Fig. 1. The structure of this decision
analytic model includes the most frequent condi-
tions affecting the biliary tree where MRCP can
provide diagnostic information comparable to
ERCP.5e8 The decision tree structure and its under-
lying assumptions were developed in discussion
with a consultant gastroenterologist, two consul-
tant radiologists and a consultant biliary pancre-
atic surgeon.
The model considers the costs from the per-
spective of the health care provider as it is the
most relevant to the decision maker within the
context of reorganising NHS resources. The time
horizon for the analysis was 12 months, the main
reason being that the relief of pain is experienced
in the short term after the removal of the stone
and that more than three-quarters of patients suf-
fering from pancreatic head lesions die within
a year of diagnosis.9
In order to facilitate the modelling, the follow-
ing main assumptions have been introduced. For
MRCP all patients incur the cost of the MRCP test.
Patients with a negative test result incur no
additional cost and achieve no gain in utility,
with false negative patients maintaining a utility
associated with an untreated condition, for exam-
ple CBDS. All patients with a positive MRCP incur
the additional cost and utility decrement of
a therapeutic ERCP, with endoscopic stent for
malignant strictures and surgery for benign stric-
tures. True positives achieve a gain in utility from
appropriate treatment and false positives achieve
no utility gain. For diagnostic ERCP the tree
follows a similar structure with the associated
additional utility decrements and mortality risks.
See also Table 1 and the HTA monograph2 for more
details of the assumptions within the model.
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Figure 1 Basic decision tree.Base case values and parameters
The parameters used in the model and the sources
from which these are derived are shown in Table 2.
Estimates of sensitivity and specificity for MRCP
and ERCP were based on the clinical effectiveness
results reported in Kaltenthaler et al.2 In line with
Table 1 Further specific assumptions
 Repeated diagnostic ERCP after failed
cannulation and repeated MRCP because of
pitfalls in interpretation are modelled
 In most cases therapeutic ERCP is performed
with sphincterotomy so the option ERCP without
sphincterotomy is not modelled
 There is some risk associated with diagnostic and
therapeutic ERCP, so a healthy patient who is
tested or treated with ERCP has a lower outcome
than a healthy patient who is not
 MRCP is generally considered risk-free, so the
utility of a healthy patient who is tested with
MRCP equals perfect healththe assumption that diagnostic ERCP is considered
as the gold-standard diagnostic test for biliary tree
investigation, we assumed perfect sensitivity and
specificity. Only accuracy of diagnostic imaging in
patients with CBDS was used in order to allow
the modelling: estimates for both CBDS and stric-
tures were not possible to pool statistically. Due
to statistically significant heterogeneity between
the studies, the median values for the sensitivity
and specificity of MRCP were used.
Peripancreatic cancer causing bile duct obstruc-
tion most commonly occurs at the head of the
pancreas, and the chances of resectability are
around 10%. The probability that curative resec-
tion is appropriate is low with the majority of
patients undergoing palliative treatment through
endoscopic stent placement.10 The most common
cause of benign biliary stricture is iatrogenic bile
trauma during cholecystectomy,11 and major bile
duct injuries usually need surgical reconstruc-
tion.12 The model assumes that surgical recon-
struction is the primary treatment for benign
extrahepatic strictures.
Economic evaluation of MRCP compared to diagnostic ERCP 15Table 2 Base case probabilities, costs and utility estimates
Diagnostic ERCP Model
distribution
MRCP Source
Mean
value
SD Mean
value
SD
Probabilities
True positive test P[Tþ r S] 1 e Fixed; for
MRCP Beta
0.925 0.075 Systematic review
True negative test P[T r H] 1 e Fixed; for
MRCP Beta
0.939 0.061 Systematic review
CDBS 0.37 e Beta 0.939 0.061 HES 2000
Malignant stricture 0.17 e Beta 0.939 0.061 HES 2000
Benign stricture 0.9 e Beta 0.939 0.061 HES 2000
Death after diagnostic ERCP 0.085 0.005 Beta e e Cotton et al. 199420
Overall complications after
diagnostic ERCP
0.055 0.002 Normal e e Cotton et al. 199420
Resection for malignant strictures 0.10 e Fixed 0.939 0.061 Clinical judgement
Endoscopic stent for malignant
strictures
0.90 e Fixed 0.939 0.061 Clinical judgement
Costs
MRI - Medical Gastroenterologya e e Normal £454 £26 NHS Reference Costs 2000/01
CT scan - Medical
Gastroenterologya
£340 £20.16 Normal £454 £26 NHS Reference Costs 2000/01
Diagnostic ERCP examination
bile duct w/o cc
£846 £100.83 Normal e e NHS Reference Costs 2000/01
Diagnostic ERCP examination
bile duct with cc
£1113 £139.83 Normal e e NHS Reference Costs 2000/01
Therapeutic ERCP - extraction
CBDS
£1108 £130.83 Normal e e NHS Reference Costs 2000/01
Surgery malignant neoplasm
extrahepatic bile ducts
(>69 y or with cc)
£2004 £134.33 Normal £454 £26 NHS Reference Costs 2000/01
Memotherm biliary stent
(palliative)
£800 £10 Normal £454 £26 Northern General
Hospital, Bradford
Royal InfirmaryBilioplasty balloon catheter £80 £10 Normal £454 £26
Utilities
Health-related QoL general
population
1 e Fixed £454 £26 Convention
MRCP examination e e Fixed 1 e Clinical judgement
Chest and back pain relating
to CBDS and strictures in
extrahepatic bile ductsb
0.89 0.003 Normal £454 £26 Cotton et al. 199420
Diagnostic ERCP procedure
only (w/o cc)c
0.9904 e Beta e e Gregor et al. 199621
ERCP with ccc 0.884 0.038 Normal £454 £26 Gregor et al. 199621
Therapeutic ERCP w/o ccc,d 0.95 e Beta £454 £26 Gregor et al. 1996,21
Bass et al. 199322
Billiary stricture surgeryc 0.759 0.016 Normal £454 £26 Bass et al. 199322
Extrahepatic malignant stricture 0.37 0.041 Normal £454 £26 Luman et al. 199710
Post-intervention for
extrahepatic malignant
stricture
0.61 0.041 Normal £454 £26 Luman et al. 199710
a Elective procedures, relating to hepato-biliary and pancreatic system HRGs section.
b Approximated same discomfort relating to gallblader, according to clinical judgement.
c Calculated as utility decrements from perfect health state.
d Given that therapeutic ERCP costs are common to both intervention and comparator, complication costs are already included
in this estimate.
16 Y. Bravo et al.The costs of healthcare resources were esti-
mated using the 2000/2001 NHS Reference Costs,
for Elective Inpatients.13 Complication costs are
also shown in Table 2. A computed tomography
(CT) scan is always performed before surgery for
suspected benign or malignant strictures, so the
Table 3 Key economic and clinical results
Mean 95% CI
Lower Upper
Key clinical results
True negative MRCP
(%) (i.e. avoiding
unnecessary
diagnostic ERCP)
30 20 40
True positive MRCP
(%) (i.e. necessary
therapeutic ERCP)
34 26 42
Death under
diag. ERCP (%)
0.1 0.1 0.1
Key economic results
Incremental QALYs 0.011 0.000 0.030
Incremental costs £149 £325 £15
INB (£20K per QALY) £364 £95 £786
Cost effectiveness
MRCP vs. ERCP
Dominant Dominant £487.45
Probability cost
saving
0.965 e e
Probability
incremental
QALYs positive
0.978 0.000 0.030
Probability cost
effectiveness
over £20K
per QALY
0.998 e eCT fixed cost is added in both branches. Utility
scores for the different health states were ob-
tained from the Harvard CUA database,14 with
the exception of utilities related to biliary tree
malignant neoplasms, which required an addi-
tional literature search. Whilst, of necessity, util-
ity scores were taken from the international
literature, all the health state valuations incorpo-
rated in the model used the EQ-5D generic
measure. Those utilities reported by clinicians
were preferred to those reported by patients
because of the peculiarities of MRCP in terms of
patient satisfaction: in spite of being a non-invasive
procedure MRCP scores lower than expected by
clinicians because of noise and claustrophobic
related reasons.2 Since we only considered a
12 months time horizon discounting of costs and
outcomes was not carried out.
The base case results are reported for a pop-
ulation at 37% risk of CBDS, 17% risk of malignan-
cies and 15% risk of benign strictures, according to
Finished Clinical Episode (FCE) records. Probabili-
ties of events are proportions so the beta distri-
bution has been used to estimate the probability of
having a CBDS, a malignant stricture or a benign
stricture, adding up to 69% risk of having an
obstruction. Multivariate sensitivity analysis, using
Monte Carlo simulation, is presented for the base
case population, together with a range of popula-
tions at different risks of CBDS.
Results
The key clinical and economic results for patients
with a baseline 31% likelihood of normal ducts, or-500
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Figure 2 Cost Effectiveness Plane for MRCP vs Diagnostic ERCP.
Economic evaluation of MRCP compared to diagnostic ERCP 17minor conditions that might require only expectant
management, are shown in Table 3. Cost-
effectiveness results have been displayed on the
cost-effectiveness plane in Fig. 2, this indicates
the high probability that MRCP dominates ERCP,
that is, MRCP results in an improved quality of
life and saves money.
The probability of avoiding unnecessary diag-
nostic ERCP, that is the probability of a true
negative MRCP, is estimated at 30%. These patients
could avoid the unnecessary risk of complications
and death associated with diagnostic ERCP, with an
overall expected QALY gain estimated at 0.011
(95% CI 0.0e0.03).
The probability that MRCP is cost saving is
estimated at approximately 97%, with an overall
expected saving of £149 (95% CI £325 to £15).
From this result, we can infer that the cost
savings in terms of avoided complications for
healthy patients (i.e. true negatives) can compen-
sate for the added diagnostic costs in those
patients who need therapeutic intervention (i.e.
true positives).
The probability that imaging with MRCP has
a cost effectiveness better than £20,000 per
QALY is estimated at 99%, with an incremental
net benefit (INB) of £364 over diagnostic ERCP.
Sensitivity analyses
The economic impact of MRCP within different
risk groups is explored in Table 4 and the cost
effectiveness acceptability curves (CEACs) are
presented in Fig. 3. The probability of MRCP being
cost-effective decreases as the probability of
CBDS increases. At a risk of CBDS of 70%, the
probability of MRCP being cost-effective compared
to diagnostic ERCP at a threshold of £20,000 per
QALY is below 50%, in fact diagnostic ERCP is
the dominant strategy with an expected QALY
gain of 0.004 (95% CI 0.005 to 0.016) and esti-
mated cost savings of £81 (95% CI £96 to £222).
At a risk of CBD stones around 60%, MRCP is esti-
mated to be cost neutral when compared with
ERCP.
Discussion
It is remarkable that although ERCP has been
assumed to be a true gold standard, with perfect
specificity and sensitivity, MRCP is still very likely
to be considered economically attractive. The
baseline estimate is that MRCP would be both
cost saving and result in improved quality of life
compared to diagnostic ERCP.T
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Figure 3 Family of cost effectiveness acceptability curves for MRCP, with four levels of risk of CBDS.Although the perspective of the economic
evaluation was the NHS as recommended by the
National Institute for Clinical Excellence,15 a soci-
etal perspective would have included an account
of patients’ time and personal costs and loss of
production due to treatment and poor health.
Due to the fact that there is likely to be little
difference in the relative impact of societal
valuation between the interventions and health
outcomes, with potentially a small bias in favour
of the less invasive intervention, MRCP, the
results are likely to be robust to a change in
perspective.
One potentially negative consequence of using
MRCP as the initial diagnostic technique in eval-
uating suspected biliary obstruction is that it
may delay therapeutic intervention in cases
where this is required. No quantitative evidence
was available concerning the potential magnitude
of this risk although to a large extent it will be
dependent on logistic factors determining the
delay between diagnostic and therapeutic proce-
dures. A potential benefit of MRCP not captured in
the analysis is the use of the magnetic resonance
images for presurgical staging of perampullary
cancers and additional information about the
state of the pancreaticobiliary duct.16,17 Quanti-
fying the impact on improved final outcomes is
not possible from current data sources. The
economic impact of considering repeated diag-
nostic ERCP after failed cannulation or repeated
MRCP, because of pitfalls in interpretation, was
examined in an alternative model and these mod-
ifications did not affect the main economic
results.Only one other economic analysis evaluating
MRCP compared to diagnostic ERCP has been
identified and this was limited to the management
of acute biliary pancreatitis.18 These results
showed that the economics of MRCP in patients
with acute biliary pancreatitis were highly depen-
dent on the probability of CBDS. At probabilities of
CBDS higher than 58%, ERCP was reported to be the
least expensive strategy. Our analysis is consistent
with these results.
Many of the limitations in the technology
assessment relate to the poor design and reporting
of comparative studies available, in particular on
diagnostic test accuracy compared to final di-
agnosis and impact on clinical practice. The fact
that ERCP is not a perfect gold standard reference
test means that the diagnostic accuracy of MRCP
may be under or over estimated. The clinical
impact of these issues is discussed by Kaltenthaler
et al.2 but this assumption also means that the
economics of MRCP may well also be under or
over estimated depending on the true accuracy
of ERCP. Problems with comparative studies of
alternative diagnostic strategies for pancreatico-
biliary conditions have also been recently noted
elsewhere.19 Ideally, the decision analytic model
would use a ROC curve analysis of sensitivity and
specificity to capture interdependence and the
impact of variation in implied diagnostic thresh-
olds and would be based upon comparative studies
of the interventions measuring their impact on
final outcomes.
Whilst MRCP might have economic benefits
compared with diagnostic ERCP, one potentially
constraining factor is the availability of
Economic evaluation of MRCP compared to diagnostic ERCP 19adequate MRI technology at hospital level and
length of waiting time. However, ERCP is also
subject to variation in operator ability and skill
and depends on the availability of skilled radiog-
raphers and radiologists to carry out and in-
terpret the imaging. In order to understand the
real opportunity costs associated with perform-
ing MRCP on a routine basis, studies are needed
to assess the relative benefits from access to
MRI services, so priorities can be addressed
rationally.
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